Sera Prognostics, Inc. Class A (SERA)

Over the past six months, several events have impacted Sera Prognostics' stock. The company reported its second-quarter 2025 financial results on August 6, 2025, followed by its third-quarter 2025 financial results on November 13, 2025. In November 2025, Sera Prognostics received an analyst upgrade to "Buy" from Zacks Investment Research and announced the publication acceptance for its PRIME study. On January 8, 2026, Sera Prognostics posted a new investor presentation to its corporate website. Despite these developments, the company's stock experienced a significant decline of approximately 40% since January 2024, and insider selling has been noted.

There is no specific information available in the provided search results to indicate demand seasonality for Sera Prognostics, Inc.'s products and services. The company's focus on pregnancy-related diagnostics suggests a relatively consistent demand driven by birth rates, rather than seasonal fluctuations.

Sera Prognostics, Inc. develops and commercializes blood-based biomarker tests and predictive analytic products and services. Its primary product is the PreTRM® test, a non-invasive blood test designed to predict an expectant mother's individualized risk of spontaneous premature birth, administered during weeks 18 to 20 of gestation. Sera Prognostics is also developing a pipeline of other blood-based biomarker tests for major pregnancy-related conditions.

Sera Prognostics, Inc. is headquartered in Salt Lake City, Utah, United States. The company is actively working on expanding its market reach, with plans for European market entry and regulatory submission in early 2026. Domestically, Sera Prognostics is engaging with Medicaid plans across thirteen states in the U.S., including an inaugural pilot program in Nevada.

In the past year, Sera Prognostics has focused on enhancing its brand reputation through scientific validation and strategic engagements. The company announced the publication acceptance for its PRIME study in November 2025 and a landmark study revealing the PreTRM test and targeted interventions ushering in a new era of personalized prenatal care on January 8, 2026. Additionally, a large study finding that the maternal biomarker test reduces neonatal morbidities and improves outcomes was reported on February 3, 2025. Sera Prognostics also presented at the 43rd Annual J.P. Morgan Healthcare Conference on January 6, 2025.

The ownership structure of Sera Prognostics (SERA) is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 31.28% to 54.64% of the company's stock, with major holders including Baker Brothers Life Sciences, L.P., and others. Insiders own about 7.37% to 15.80% of the stock, with Felix Baker owning the most shares.